Abarelix
A hormone-blocking injection used in men with advanced prostate cancer who cannot or choose not to have surgical removal of the testes. It suppresses the production of testosterone, which fuels prostate cancer growth, without the initial hormone surge that some other treatments cause. Because of a risk of serious allergic reactions, it is only administered in a clinical setting where the patient can be observed for 30 minutes afterward.
Khối lượng phân tử
1416,1000 g/mol
LogP
3,70
TPSA
425,00 Ų
Lipinski RO5
Không đạt
Lĩnh vực điều trị
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
InChI
InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1
Molecular Formula
C72H95ClN14O14
HBD / HBA
13 / 16
Liên kết có thể quay
38
Nguyên tử nặng
101
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
A hormone-blocking injection used in men with advanced prostate cancer who cannot or choose not to have surgical removal of the testes. It suppresses the production of testosterone, which fuels prostate cancer growth, without the initial hormone surge that some other treatments cause. Because of a risk of serious allergic reactions, it is only administered in a clinical setting where the patient can be observed for 30 minutes afterward.
Yes, Abarelix is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1252. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 16131215. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="abarelix"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/abarelix/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/abarelix/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/abarelix/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="abarelix"></drugfyi-drug>